Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$23.41M$23.41M−50.6% vs Q1 2021 Net Income-$75.97M-$75.97MN/M vs Q1 2021 EPS Diluted-$1.20-$1.20N/M vs Q1 2021 Operating Income-$71,981,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$55,451,000N/M Margins · derivedOperating margin-307.5%−207.2 pt vs Q1 2021
Net margin-324.5%−210.9 pt vs Q1 2021
ended Mar 31, 2022 · filed May 5, 2022 · 35 d after period end